Chemours extends $1.05 billion term loan to 2032, adds receivables program
Chemours amended its credit agreement on October 15, 2025, extending the maturity of its $1,050,000,000 senior secured Term Loan B-3 US$ Facility from August 18, 2028 to October 15, 2032, with a new margin of Term SOFR + 3.50% or base rate plus 2.50%. Separately, Chemours subsidiaries agreed to sell up to €180 million of eligible receivables to BNP Paribas Factor GmbH under a Receivables Purchase Agreement, and Chemours accepted joint and several liability for the subsidiaries' obligations under it.
Key points
- Term Loan B-3 US$ Facility of $1,050,000,000 extended from August 18, 2028 to October 15, 2032
- Margin set at Term SOFR + 3.50% or adjusted base rate plus 2.50%, at the Company's election
- Receivables sales of up to €180 million to BNP Paribas Factor GmbH; initial term through October 14, 2026, with automatic one-year extension
- Chemours accceded to joint and several liability for the Chemours Sellers' obligations on October 14, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.